Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | ONCOLOGY//CELL BIOLOGY//BIOCHEMISTRY & MOLECULAR BIOLOGY | 2934640 |
161 | 3 | MENOPAUSE//ISOFLAVONES//TAMOXIFEN | 62578 |
552 | 2 | TAMOXIFEN//ESTROGEN RECEPTOR//AROMATASE INHIBITORS | 15141 |
4626 | 1 | AROMATASE INHIBITORS//ANASTROZOLE//AROMATASE INHIBITOR | 1778 |
Terms with highest relevance score |
rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|---|
1 | AROMATASE INHIBITORS | authKW | 1833616 | 18% | 32% | 322 |
2 | ANASTROZOLE | authKW | 748656 | 8% | 32% | 134 |
3 | AROMATASE INHIBITOR | authKW | 718350 | 10% | 23% | 176 |
4 | EXEMESTANE | authKW | 610745 | 5% | 36% | 97 |
5 | ADJUVANT ENDOCRINE THERAPY | authKW | 489106 | 2% | 64% | 43 |
6 | LETROZOLE | authKW | 467036 | 7% | 20% | 133 |
7 | TAMOXIFEN | authKW | 442087 | 19% | 8% | 332 |
8 | OVARIAN ABLATION | authKW | 347379 | 2% | 70% | 28 |
9 | ENDOCRINE THERAPY | authKW | 326794 | 7% | 16% | 117 |
10 | ORAL CHEMOTHERAPY | authKW | 263257 | 3% | 29% | 52 |
Web of Science journal categories |
chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | Oncology | 36342 | 73% | 0% | 1298 |
2 | Obstetrics & Gynecology | 2366 | 12% | 0% | 207 |
3 | Nursing | 758 | 4% | 0% | 73 |
4 | Health Care Sciences & Services | 519 | 4% | 0% | 73 |
5 | Endocrinology & Metabolism | 202 | 5% | 0% | 95 |
6 | Medicine, General & Internal | 200 | 7% | 0% | 117 |
7 | Rehabilitation | 167 | 2% | 0% | 43 |
8 | Pharmacology & Pharmacy | 111 | 7% | 0% | 130 |
9 | Health Policy & Services | 26 | 1% | 0% | 16 |
10 | Integrative & Complementary Medicine | 15 | 1% | 0% | 9 |
Address terms |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | SENOL EASTERN SWITZERLAND | 77051 | 1% | 43% | 10 |
2 | IBCSG STAT | 72354 | 1% | 29% | 14 |
3 | FRENCH BREAST CANC GRP | 70897 | 0% | 100% | 4 |
4 | INT BREAST CANC STUDY GRP STAT | 66800 | 0% | 54% | 7 |
5 | GYNECOL ENDOCRINOL ONCOL | 63298 | 0% | 71% | 5 |
6 | AUSTRALIAN NEW ZEALAND BREAST CANC TRIALS GRP | 59558 | 1% | 31% | 11 |
7 | CANC GENET PREVENT SCREENING | 53173 | 0% | 100% | 3 |
8 | ENDOCRINOL REPROD MED OSTEOPOROSIS | 51262 | 1% | 32% | 9 |
9 | NEWCASTLE MATER HOSP | 42002 | 0% | 30% | 8 |
10 | PATRICIA RICHIE CANC CARE | 39878 | 0% | 75% | 3 |
Journals |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | BREAST | 58629 | 5% | 4% | 91 |
2 | BREAST CANCER RESEARCH AND TREATMENT | 52776 | 8% | 2% | 149 |
3 | CLINICAL BREAST CANCER | 36390 | 2% | 5% | 41 |
4 | JOURNAL OF CLINICAL ONCOLOGY | 19252 | 8% | 1% | 134 |
5 | BREAST CARE | 13141 | 1% | 4% | 21 |
6 | ANNALS OF ONCOLOGY | 12327 | 4% | 1% | 77 |
7 | CLINICAL JOURNAL OF ONCOLOGY NURSING | 9058 | 1% | 2% | 21 |
8 | CANCER TREATMENT REVIEWS | 7881 | 2% | 1% | 30 |
9 | JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 7835 | 1% | 4% | 11 |
10 | BREAST CANCER | 5767 | 1% | 2% | 15 |
Author Key Words |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | AROMATASE INHIBITORS | 1833616 | 18% | 32% | 322 | Search AROMATASE+INHIBITORS | Search AROMATASE+INHIBITORS |
2 | ANASTROZOLE | 748656 | 8% | 32% | 134 | Search ANASTROZOLE | Search ANASTROZOLE |
3 | AROMATASE INHIBITOR | 718350 | 10% | 23% | 176 | Search AROMATASE+INHIBITOR | Search AROMATASE+INHIBITOR |
4 | EXEMESTANE | 610745 | 5% | 36% | 97 | Search EXEMESTANE | Search EXEMESTANE |
5 | ADJUVANT ENDOCRINE THERAPY | 489106 | 2% | 64% | 43 | Search ADJUVANT+ENDOCRINE+THERAPY | Search ADJUVANT+ENDOCRINE+THERAPY |
6 | LETROZOLE | 467036 | 7% | 20% | 133 | Search LETROZOLE | Search LETROZOLE |
7 | TAMOXIFEN | 442087 | 19% | 8% | 332 | Search TAMOXIFEN | Search TAMOXIFEN |
8 | OVARIAN ABLATION | 347379 | 2% | 70% | 28 | Search OVARIAN+ABLATION | Search OVARIAN+ABLATION |
9 | ENDOCRINE THERAPY | 326794 | 7% | 16% | 117 | Search ENDOCRINE+THERAPY | Search ENDOCRINE+THERAPY |
10 | ORAL CHEMOTHERAPY | 263257 | 3% | 29% | 52 | Search ORAL+CHEMOTHERAPY | Search ORAL+CHEMOTHERAPY |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 1 |